Singapore markets closed
Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,105.11 -11.06 (-0.22%) Dow
38,201.87 -184.22 (-0.48%) Nasdaq
15,937.59 -45.50 (-0.28%) Bitcoin USD
62,955.66 -677.18 (-1.06%) CMC Crypto 200
1,306.17 -32.89 (-2.46%)
REGENXBIO Inc. (RGNX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 09:51AM EDT. Market open.
| Previous close | 16.05 |
| Open | 15.79 |
| Bid | 15.79 x 100 |
| Ask | 16.07 x 100 |
| Day's range | 15.41 - 15.97 |
| 52-week range | 11.83 - 28.80 |
| Volume | |
| Avg. volume | 737,374 |
| Market cap | 781.005M |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures
Key Insights Significantly high institutional ownership implies REGENXBIO's stock price is sensitive to their trading...
- GuruFocus.com
Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares
Regenxbio Inc (NASDAQ:RGNX), a biotechnology company focused on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy, has reported an insider sale according to a recent SEC filing.
- GuruFocus.com
Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares
Regenxbio Inc (NASDAQ:RGNX), a biotechnology company focused on the development, commercialization, and licensing of recombinant viral vectors for use in gene therapy, has reported an insider sale according to a recent SEC filing.
© 2024 Yahoo. All rights reserved.